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Abstract
Background: Recent studies have shown that the phosphatidylinositol 3-kinase (PI3K) signaling pathway is
important regulator of many cellular events, including apoptosis, proliferation and motility. PI3K pathway alterations
(PIK3CA gene mutations and/or amplification) have been observed in various human tumours. In the majority of
diagnosed cases, mutations are localized in one of the three “hot spots” in the gene, responsible for coding
catalytic subunit a of class I PI3K (PIK3CA). Mutations and amplification of PIK3CA gene are characteristic for thyroid
cancer, as well.
Methods: The aim of our study was to examine a gene expression level of PIK3CA in fine-needle aspiration biopsy
(FNAB) thyroid specimens in two types of thyroid lesions, papillary thyroid carcinoma (PTC) and non-toxic goitre
(NTG). Following conventional cytological examination, 42 thyroid FNAB specimens, received from patients with
PTC (n = 20) and NTG (n = 22), were quantitatively evaluated regarding PIK3CA expression level by real-time PCR in
the ABI PRISM® 7500 Sequence Detection System.
Results: Significantly higher expression level (RQ) of PIK3CA in PTC group has been noted in comparison with NTG
group (p < 0.05).
Conclusion: These observations may suggest role of PIK3CA alterations in PTC carcinogenesis.
Background
Phosphatidylinositol 3-kinase (phosphoinositide 3-
kinase, PI3K) family is composed of three classes of
kinases. Class I PI3K regulates cell growth, proliferation
and survival. It consists of two subclasses: Ia - dimeric
components, comprised of catalytic subunits: p110a,
p110b,p 1 1 0 δ, associated with p85 regulatory subunit
and subclass Ib, which is heterodimer consisting of
p110g catalytic subunit, connected with p101 regulatory
subunit. Subclass Ia is responsible for transmission sig-
nals from receptor tyrosine kinase - RTK (i.e. EGFR,
PDGFR). Regulation of this signal transduction pathway
is frequently disrupted in human cancers by alterations
of PI3K pathway. Among the four isoforms of the cata-
lytic subunits, the a-type has been shown to harbour
oncogenic mutations or amplifications in its gene
(PIK3CA) [1,2]. PIK3CA gene is located on chromosome
3q26.3 and consists of 20 exons, coding 1068 amino
acids and yielding a 124 kDa size protein [2]. Eighty per-
cent of the mutations in PIK3CA gene are located in
three regions within the helical (exon 9), catalytic (exon
20) and p85 binding (exon 1 and 2) domains [3]. The
location of the mutations induces one of the several dis-
tinct mechanisms [4], enhancing PIK3CA kinase activity
and Akt phosphorylation.
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PIK3CA gene has particularly been found in breast [5]
and colorectal [3] cancers. The incidence rates of these
mutations indicate that PIK3CA is one out of the two
most commonly mutated genes, identified in human
cancers (the other one being KRAS). In addition to acti-
vating mutations, PIK3CA gene amplification has also
been implicated in cancer and has been associated with
increased PI3K signaling, for instance, in ovarian [6] and
cervical [7] cancers. The increased copy number is asso-
ciated with increased cell growth and decreased apopto-
sis. The above mentioned results of numerous studies
have established the role of PIK3CA as an oncogene in
human cancers. PI3K is also thought to be involved in
the formation of metastatic phenotype and promotion of
carcinoma invasion. This phenotype appears to be inde-
pendent of kinase Akt activation.
Over the past several years, the frequency of PIK3CA
mutations and gene amplification has been analyzed in
some sporadic thyroid carcinomas [8-12]. Similarly to
other human cancers, the majority of PIK3CA gene
mutations in thyroid neoplasms has been reported in
exon 9 (helical domain) and 20 (kinase domain) [10].
Mutations in PIK3CA gene have been observed more
frequently in follicular thyroid carcinoma (FTC) and
anaplastic thyroid carcinoma (ATC), while being rather
uncommon in PTC [8,10,11]. Still, little is known about
the precise role of PIK3CA in PTC and data are not
consistent.
In the present paper, we have evaluated the relative
expression level of PIK3CA gene in PTC and NTG. Addi-
tionally, we attempted to examine a potential correlation
between PIK3CA gene expression level in FNAB speci-
mens of thyroid tissue and age and gender of patients
with PTC and NTG. To our knowledge, this is - up to-
date - the first report which provides data on these
subjects.
Methods
The patients were selected on the basis of the results
of routinely performed FNAB of the thyroid gland.
Cytological specimens from 42 patients (35 women,
7 men) were examined, including 20 patients with
PTC, and 22 patients with NTG. All tissue samples
were taken after patients’ informed consents were
obtained. PTC and NTG were diagnosed, according to
cytological evaluation of FNAB specimens. Each aspi-
rate was smeared for routine cytology, while the
remaining part of aspirate was immediately washed out
of the needle. The cells, obtained from the needle,
were used in further investigation. Macroscopically
unchanged thyroid tissue, surgically removed from
patients with thyroid cancer, served as a control for
real-time PCR experiment.
Total RNA from FNAB was extracted by use of an
RNeasy Micro Kit (Qiagen, Hilden, Germany), based on
modified Chomczyński and Sacchi’s method, according
to manufacturer’s recommendations. The purity of total
RNA was assessed by NanoDrop® ND-100 spectrophoto-
metr (data not presented). One hundred nanogram of
t o t a lR N Aw a su s e di nt h ef i r s ts t r a n dc D N As y n t h e s i s
with TaqMan® Reverse Transcripton Reagents (Applied
Biosystems, Branchburg, New Jersey, USA), according to
manufacturer’s instruction.
Real-time PCR was performed on the ABI PRISM®
7500 Sequence Detection System (Applied Biosystem,
Foster City, CA, USA), by using TaqMan® Universal
PCR Master Mix (Applied Biosystem) and TaqMan®
Gene Expression Assays probe and primer mix (Applied
Biosystem), according to the manufacturer’s specifica-
tion. The Assay Identification number of PIK3CA was:
Hs00180679_ml. Gene-specific probes were labeled by
u s i n gr e p o r t e rd y eF A Ma tt h e5 ’end. A non-fluorescent
quencher and the minor grove binder were linked at the
3’end of probe. Thermal cycler conditions were as fol-
lows: hold for 10 min. at 95°C, follow by two-step PCR
for 50 cycles of 95°C for 15 s, followed by 60°C for
1 min. Amplification reactions in triplicate for each
sample were performed and the results were normalized
to the ACTB gene expression level.
An analysis of relative gene expression data was per-
formed, using the 2
-ΔΔCT method on an ABI PRISM®
7500 Sequence Detection System Software (Applied Bio-
systems, Foster City, CA, USA). The fold change in stu-
died gene expression, normalised to endogenous
control, was calculated using: RQ = 2
-ΔΔCT (Table 1 and
Table 2).
Statistical analysis
Analysis was performed with statistical software package
Statistica 7. Basic measures of location (i.e. mean, med-
ian), measures of dispersion (SD, SEM) and minimum
and maximum and lower quartile and upper quartile
values were calculated to provide detailed descriptions of
gene expressions in selected groups. Subsequently, the
data were statistically analyzed, using non-parametric
Mann-Whitney’s U test, in order to compare the level of
expression values (RQ) among the two studied indepen-
dent groups (PTC, NTG). Spearman’s rank correlation
coefficient was used to describe the correlation between
PIK3CA gene expression level and patient’s age in studied
groups. Statistical evaluations of correlation between the
gene expressions and gender were performed using the
non-parametric Mann-Whitney’s U-test.
Results
Our analysis (Mann-Whitney’s U-test), used for RQ
comparison, revealed statistically significant (p < 0,05)
Wojciechowska-Durczyńska et al. Thyroid Research 2010, 3:5
http://www.thyroidresearchjournal.com/content/3/1/5
Page 2 of 5differences in PIK3CA gene expression levels between
PTC and NTG. The expression level (RQ) of the
PIK3CA was higher in PTC group, in comparison with
NTG group. There was no correlation with patient’ss e x
and age (p > 0.05) (Spearman’s rank correlation test and
Mann-Whitney’s U-test). The box-and-whisker plot dia-
grams, representing the different expression levels of
PIK3CA (median and mean values) in PTC and NTG
group, are shown in Figure 1 and Figure 2, respectively.
Discussion
In our study, we have clearly presented significantly
higher PIK3CA gene expression in FNAB-derived sam-
ples of PTC, in comparison with NTG group. Thus,
overexpression of PIK3CA gene within PTC can be
regarded as a potential genetic event in thyroid carcino-
genesis. Our results are consistent with data published
by Abubaker et al. [12] who have presented the high
incidence of PIK3CA amplification in PTC among the
Middle East population. PIK3CA amplifications and
mutations (exon 9 and 20) were discovered in 53.1%
and 2% of PTC group, respectively [12].
So far, insulin-like growth factor I (IGF-I) and trans-
forming growth factor a (TGF-a) receptors with tyro-
sine kinase activity have been proved to commonly be
overexpressed in thyroid neoplasms. Furthermore, auto-
endocrine effects of IGF-I and TGF-a have been
noticed, suggesting their association with cancer pro-
gression. The increased signaling in these receptors,
mediating thyroid cancer development, activates PI3K
pathway which is a major intracellular downstream
mediator [13]. It may explain the increased activation of
PI3K pathway in thyroid malignancies, documented in
our study.
Moreover, genetic alterations of PIK3CA gene have
been proved to increase expression of PIK3CA gene, as
well. Amplifications and mutations in PIK3CA gene
have been reported in many human cancer types,
including thyroid cancer. To date, the increased activity
of PI3K pathway was noted particularly in sporadic thyr-
oid carcinomas, especially in FTC and ATC. Previous
studies have revealed higher prevalence of PIK3CA copy
gain in ATC (42%) in comparison with FTC (28%),
which may indicate that PIK3CA gene participates in
the progression of FTC toward more aggressive types of
cancer [10,14]. Furthermore, available data indicate that
the occurrence rate of PIK3CA mutations in PTC is low
and the rate in question is reported to be in range from
0 to 3% [8-12]. Gene amplification of PIK3CA is more
common (ranges from 5 to 14%) in PTC patients, how-
ever, still it is less frequent in comparison with FTCs
[8-12]. These findings support the hypothesis that
PIK3CA is essential for PTC carcinogenesis and for an
invasive type of cancer development. Supporting these
Table 1 Gender, age, ddCT and RQ values in PTC group
No. Gender Age ddCT values RQ values
1. M 58 -7.105 137.671
2. M 64 -3.288 9.77
3. F 49 -2.239 4.721
4. F 67 -5.185 36.378
5. F 28 -0.307 1.237
6. F 56 -7.224 149.519
7. F 57 -3.675 12.771
8. F 39 -2.968 7.827
9. F 36 -4.017 16.187
10. F 49 -4.2 18.373
11. F 28 -1.837 3.572
12. F 19 -4.923 30.343
13. M 61 -1.418 2.672
14. F 28 0.214 0.862
15. F 50 -0.689 1.612
16. F 53 -1.789 3.455
17. F no data -2.757 6.758
18. F 52 -4.985 31.676
19. F 24 -3.735 13.311
20. M 56 -3.94 15.345
Table 2 Gender, age, ddCT and RQ values in NTG group
No. Gender Age ddCT values RQ values
1. F 77 -5.493 45.046
2. F 27 -2.853 7.223
3. F 68 -2.268 4.817
4. F 62 -0.844 1.795
5. F 43 -1.852 3.609
6. F 71 8.186 0.03
7. F 43 -3.068 8.386
8. F 49 -0.851 1.804
9. M 61 -4.473 22.213
10. M 44 8.492 0.03
11. F 79 7.237 0.007
12. F 54 5.855 0.009
13. F 50 8.704 0.002
14. F 51 -1.478 2.785
15. M 55 -1.362 2.571
16. F 41 -0.097 1.069
17. F 68 -3.158 8.927
18. F 87 -2.334 5.046
19. F 62 0.291 0.813
20. F 64 -3.88 14.719
21. F 43 -1.252 2.382
22. F 70 -4.115 17.323
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Page 3 of 5Figure 1 Box-and-whisker plots, representing the expression of PIK3CA gene in the studied groups (PTC, NTG). The results are calculated
as RQ values. Whiskers represent median and minimum and maximum values for particular groups. Boxes represent lower quartile and upper
quartile. The results were statistically analyzed, using Man-Whitney’s U test (p < 0.05).
Figure 2 Box-and-whisker plots, representing the expression of PIK3CA gene in the studied groups (PTC, NTG). The results are calculated
as RQ values. Whiskers represent means ± SD (standard deviation) for particular groups. Boxes represent means ± SEM (standard error of mean).
The results were statistically analyzed, using Man-Whitney’s U test (p < 0.05).
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PIK3CA copy gain with high-risk clinico-pathological
features in thyroid cancer; the authors suggested a pos-
sible role of that amplification in thyroid tumor
progression.
However, basing on the well-defined role for BRAF
and ERK signaling, PIK3CA alterations are rather unli-
kely to play alone a central role in PTC carcinogenesis
[14]. Far more possible, PIK3CA genetic changes may
coparticipate in multi-step model of carcinogenesis
pathway, likewise in the colorectal cancer, though these
interactions require further evaluation.
On the other hand, mutant PI3K may be an important
goal for future targeted tumor therapy. PIK3CA muta-
tions enhance PI3K function, which - contrary to func-
tion loss - is much easier to control. Still, mostly
enigmatic molecular pathomechanism of PIK3CA activ-
ity increase remains the greatest barrier to obtain highly
specific and effective targeted therapy. This task requires
further investigations, according to results of clinical
studies [15].
Conclusions
In conclusion, our results on overexpression of PIK3CA
in PTC, suggest that this gene is involved, to some
degree, in pathogenesis of PTC, likewise in more aggres-
sive types of the cancer in question. The definite role of
PIK3CA in multi-step carcinogenesis and acquisition of
invasive capacity of thyroid cancers remains to be
determined.
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